[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002
|
[3]
|
吴春晓, 顾凯, 龚杨明, 郑荣寿, 王少明, 陈茹, 张思维, 施燕, 魏文强, 付晨, 赫捷. 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020(4): 241-245.
|
[4]
|
Xu, R., Wang, W., Zhu, B., Lin, X., Ma, D., Zhu, L., et al. (2020) Disease Characteristics and Treatment Patterns of Chinese Pa-tients with Metastatic Colorectal Cancer: A Retrospective Study Using Medical Records from China. BMC Cancer, 20, Article No. 131. https://doi.org/10.1186/s12885-020-6557-5
|
[5]
|
Van Cutsem, E., Cervantes, A., Nordlinger, B., Arnold, D. and ESMO Guidelines Working Group (2014) Metastatic Colorectal Cancer: ESMO Clinical Practice Guide-lines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, iii1-9. https://doi.org/10.1093/annonc/mdu260
|
[6]
|
Lee, R.M., Cardona, K. and Russell, M.C. (2019) Historical Perspec-tive: Two Decades of Progress in Treating Metastatic Colorectal Cancer. Journal of Surgical Oncology, 119, 549-563. https://doi.org/10.1002/jso.25431
|
[7]
|
Islami, F., Goding Sauer, A., Miller, K.D., et al. (2018) Proportion and Number of Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in the United States. CA: A Cancer Journal for Clinicians, 68, 31-54.
https://doi.org/10.3322/caac.21440
|
[8]
|
Diaz, L.A., Shiu, K.K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., et al. (2022) Pembrolizumab versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Meta-static Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 23, 659-670.
https://doi.org/10.1016/S1470-2045(22)00197-8
|
[9]
|
Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.J., Morse, M.A., et al. (2017) Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Mi-crosatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study. The Lancet Oncology, 18, 1182-1191.
https://doi.org/10.1016/S1470-2045(17)30422-9
|
[10]
|
Afrăsânie, V.A., Marinca, M.V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A.M., Miron, L. and Rusu, C. (2019) KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer-Practical Implications for the Clinician. Radiology and Oncology, 53, 265-274. https://doi.org/10.2478/raon-2019-0033
|
[11]
|
Cefalì, M., Epistolio, S., Palmarocchi, M.C., Frattini, M. and De Dosso, S. (2021) Research Progress on KRAS Mutations in Colorectal Cancer. Journal of Cancer Metastasis and Treatment, 7, Article No. 26.
https://doi.org/10.20517/2394-4722.2021.61
|
[12]
|
Testa, U., Pelosi, E. and Castelli, G. (2018) Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences (Basel), 6, Article No. 31.
https://doi.org/10.3390/medsci6020031
|
[13]
|
Modest, D.P., Pant, S. and Sartore-Bianchi, A. (2019) Treatment Se-quencing in Metastatic Colorectal Cancer. European Journal of Cancer, 109, 70-83. https://doi.org/10.1016/j.ejca.2018.12.019
|
[14]
|
Venook, A.P., Niedzwiecki, D., Lenz, H.J., Innocenti, F., Fruth, B., Meyerhardt, J.A., et al. (2017) Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on Overall Survival in Patients with KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA, 317, 2392-2401.
https://doi.org/10.1001/jama.2017.7105
|
[15]
|
Tournigand, C. andré, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et al. (2004) FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Clinical Oncology, 22, 229-237. https://doi.org/10.1200/JCO.2004.05.113
|
[16]
|
Grothey, A., Sargent, D., Goldberg, R.M. and Schmoll, H.J. (2004) Survival of Patients with Advanced Colorectal Cancer Improves with the Availability of Fluorouracil-Leucovorin, Iri-notecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 22, 1209-1214. https://doi.org/10.1200/JCO.2004.11.037
|
[17]
|
Hammond, W.A., et al. (2016) Pharmacologic Resistance in Colo-rectal Cancer: A Review. Therapeutic Advances in Medical Oncology, 8, 57-84. https://doi.org/10.1177/1758834015614530
|
[18]
|
Biller, L.H. and Schrag, D. (2021) Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA, 325, 669-685. https://doi.org/10.1001/jama.2021.0106
|
[19]
|
Zarour, L.R., Anand, S., Billingsley, K.G., Bisson, W.H., Cercek, A., Clarke, M.F., et al. (2017) Colorectal Cancer Liver Metas-tasis: Evolving Paradigms and Future Directions. Cellular and Molecular Gastroenterology and Hepatology, 3, 163-173. https://doi.org/10.1016/j.jcmgh.2017.01.006
|
[20]
|
Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1
|
[21]
|
Guan, Z.Z., Xu, J.M., Luo, R.C., Feng, F.Y., Wang, L.W., Shen, L., et al. (2011) Efficacy and Safety of Bevacizumab plus Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer: A Randomized Phase III ARTIST Trial. Chinese Journal of Cancer, 30, 682-689. https://doi.org/10.5732/cjc.011.10188
|
[22]
|
Parakrama, R., Fogel, E., Chandy, C., et al. (2020) Immune Characteri-zation of Metastatic Colorectal Cancer Patients Post Reovirus Administration. BMC Cancer, 20, Article No. 569. https://doi.org/10.1186/s12885-020-07038-2
|
[23]
|
Liu, X., Guo, A., Tu, Y., et al. (2020) Fruquintinib Inhibits VEGF/ VEGFR2 Axis of Choroidal Endothelial Cells and M1-Type Macrophages to Protect Against Mouse La-ser-Induced Choroidal Neovascularization. Cell Death & Disease, 11, Article No. 1016. https://doi.org/10.1038/s41419-020-03222-1
|
[24]
|
Li, J., Qin, S., Xu, R.H., Shen, L., Xu, J., Bai, Y., et al. (2018) Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA, 319, 2486-2496. https://doi.org/10.1001/jama.2018.7855
|
[25]
|
Burki, T.K. (2018) Fruquintinib for Previously Treated Meta-Static Colorectal Cancer. The Lancet Oncology, 19, e388. https://doi.org/10.1016/S1470-2045(18)30503-5
|
[26]
|
Lito, P., Solomon, M., Li, L.-S., Hansen, R. and Rosen, N. (2016) Allele-Specific Inhibitors Inactivate Mutant KRAS G12C by a Trapping Mechanism. Science, 351, 604-608. https://doi.org/10.1126/science.aad6204
|
[27]
|
Canon, J., Rex, K., Saiki, A.Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C.G., Koppada, N., et al. (2019) The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity. Nature, 575, 217-223.
https://doi.org/10.1038/s41586-019-1694-1
|
[28]
|
Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunothera. Clinics in Chest Medicine, 41, 237-247. https://doi.org/10.1016/j.ccm.2020.02.010
|
[29]
|
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., et al. (2022) How to Overcome Tumor Resistance to Anti-PD-1/PD-L1 Therapy by Immunotherapy Modifying the Tumor Microenvironment in MSS CRC. Clinical Immunology, 237, Article ID: 108962. https://doi.org/10.1016/j.clim.2022.108962
|
[30]
|
Pu, Y. and Ji, Q. (2022) Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Frontiers in Immunology, 13, Article ID: 874589. https://doi.org/10.3389/fimmu.2022.874589
|
[31]
|
Chae, Y.K., Arya, A., Iams, W., Cruz, M.R., Chandra, S., Choi, J. and Giles, F. (2018) Current Landscape and Future of Dual Anti-CTLA4 and PD‑1/PD‑L1 Blockade Immunotherapy in Cancer: Lessons Learned from Clinical Trials with Melanoma and Non‑Small Cell Lung Cancer (NSCLC). The Journal for ImmunoTherapy of Cancer, 6, 39.
https://doi.org/10.1186/s40425-018-0349-3
|
[32]
|
Stein, A., Moehler, M., Trojan, J., Goekkurt, E. and Vogel, A. (2018) Immuno-Oncology in GI Tumours: Clinical Evidence and Emerging Trials of PD-1/PD-L1 Antagonists. Critical Reviews in Oncology/Hematology, 130, 13-26.
https://doi.org/10.1016/j.critrevonc.2018.07.001
|
[33]
|
Le, D.T., Kim, T.W., Van Cutsem, E., et al. (2020) Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology, 38, 11-19. https://doi.org/10.1200/JCO.19.02107
|
[34]
|
Le, D.T., Uram, J.N., Wang, H., et al. (2015) PD-1 Blockade in Tu-mors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520. https://doi.org/10.1056/NEJMoa1500596
|
[35]
|
Antoniotti, C., Rossini, D., Pietrantonio, F., et al. (2022) Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial. The Lancet Oncology, 23, 876-887.
https://doi.org/10.1016/S1470-2045(22)00274-1
|
[36]
|
Mettu, N.B., et al. (2019) BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study. Annals of Oncology, 30, v198-v252.
https://doi.org/10.1093/annonc/mdz246.011
|
[37]
|
Lenz, H.-J., Parikh, A.R., Spigel, D.R., et al. (2022) Nivolumab (NIVO) + 5-Fluorouracil/Leucovorin/Oxaliplatin (mFOLFOX6)/Bevacizumab (BEV) versus mFOLFOX6/BEV for First-Line (1L) Treatment of Metastatic Colorectal Cancer (mCRC): Phase 2 Results from CheckMate 9X8. Journal of Clinical Oncology, 40, Article No. 8.
https://doi.org/10.1200/JCO.2022.40.4_suppl.008
|
[38]
|
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., et al. (2022) Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Con-trolled, Phase 2 Trial. The Lancet Oncology, 23, 876-887.
https://doi.org/10.1016/S1470-2045(22)00274-1
|
[39]
|
Damato, A., Bergamo, F., Antonuzzo, L., Nasti, G., Iachetta, F., Romagnani, A., Gervasi, E., Larocca, M. and Pinto, C. (2021) FOLFOXIRI/Bevacizumab plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. Frontiers in Oncology, 11, Article ID: 766500.
https://doi.org/10.3389/fonc.2021.766500
|
[40]
|
Fang, X.F., et al. (2022) A Phase 2 Trial of Sintilimab (IBI 308) in Combination with CAPEOX and Bevacizumab (BBCAPX) as First-Line Treatment in Patients with RAS-Mutant, Mi-crosatellite Stable, Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 40, 3563. https://doi.org/10.1200/JCO.2022.40.16_suppl.3563
|
[41]
|
Ghiringhelli, F., Chibaudel, B. and Taieb, J. (2020) Dur-valumab and Tremelimumab in Combination with FOLFOX in Patients with RAS-Mutated, Microsatellite-Stable, Previ-ously Untreated Metastatic Colorectal Cancer (MCRC): Results of the First Intermediate Analysis of the Phase Ib/II MEDETREME Trial. Journal of Clinical Oncology, 38, 3006.
https://doi.org/10.1200/JCO.2020.38.15_suppl.3006
|